Efficacy of Oral directly acting antivirals HIV/HCV-coinfected patients with genotype 3 and compensated liver disease: A real world Madrid coinfection registry (MADRID-CoRe) study

Trial Profile

Efficacy of Oral directly acting antivirals HIV/HCV-coinfected patients with genotype 3 and compensated liver disease: A real world Madrid coinfection registry (MADRID-CoRe) study

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Daclatasvir/sofosbuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2017 New trial record
    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top